$24,750.00 | '
Delayed Sleep-Wake Phase Disorder | Executive Insights | US/EU5 | 2021
- DSWPD is a type of circadian rhythm sleep-wake disorder in which the sleep-wake cycle is delayed. DSWPD occurs more commonly in adolescents than in adults. In addition, the condition is highly comorbid with some psychiatric conditions, such as MDD and ASD.
- Although interviewed sleep specialists commonly diagnose DSWPD, they cite challenges in differentiating circadian DSWPD from noncircadian (i.e., behavioral) DSWPD. Interviewed psychiatrists usually consider DSWPD as secondary to a psychiatric disorder.
- No drug is currently approved for the management of DSWPD in the United States and EU5. Melatonin and some nonpharmacological approaches (e.g., light therapy) are commonly utilized in the treatment of DSWPD. However, the patient journey may differ depending on the presence or absence of a comorbid psychiatric disorder.
- Interviewed physicians cite multiple areas of unmet need in DSWPD, so opportunities exist for drug development in DSWPD. Of note, interviewed physicians have high expectations for an emerging drug in DSWPD.
Related Market Assessment Reports
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
